MAZE — Maze Therapeutics, Inc. Common Stock · rev $20.0M

Maze Therapeutics, Inc. Common Stock (MAZE) is a biotechnology company listed on US.

Latest reported MAZE revenue for 2026-06-30 was $20.0M. Net income was -$68.9M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. MAZE currently screens at market cap $525.3M.

Use this MAZE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MAZE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MAZE SEC filings page. Lician reads the product cache first so this HTML stays unique to Maze Therapeutics, Inc. Common Stock even when a live quote feed is slow.